Vigorous Gainers/Losers Roundup: Amgen (NASDAQ:AMGN), International Paper (NYSE:IP)

Amgen Inc. (NASDAQ:AMGN) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 1.91% to 159.67 with around 3.92 Million shares have changed hands in this session. Amgen (AMGN) reported that FOURIER trial evaluating whether Repatha (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease met its primary composite endpoint and the key secondary composite endpoint.

No new safety issues were observed. “In the GLAGOV study, we demonstrated that Repatha has an effect on atherosclerosis, the underlying cause of cardiovascular disease. These FOURIER results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,” said Sean Harper, executive vice president of Research and Development at Amgen. The stock is going forward its fifty-two week low with 20.28% and lagging behind from its 52-week high price with -9.10%.

Similar, the positive performance for the quarter recorded as 13.88% and for the year was 9.17%, while the YTD performance remained at 9.21%. AMGN has Average True Range for 14 days of 2.90.

International Paper Company (NYSE:IP) [Trend Analysis] retains strong position in active trade, as shares scoring -0.18% to $56.50 in active trade session, while looking at the shares volume, around 2.99 Million shares have changed hands in this session. International Paper Co. (IP) declared that its Q4 profit of $218 million. The Memphis, Tennessee-based company said it had profit of 53 cents per share. Earnings, adjusted for non-recurring costs, were 73 cents per share. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 71 cents per share.

The global paper and packaging company posted revenue of $5.38 billion in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $5.31 billion. For the year, the company declared profit of $904 million, or $2.18 per share. Revenue was declared as $21.08 billion. The firm has institutional ownership of 83.90%, while insider ownership included 0.60%. IP attains analyst recommendation of 2.40 with week’s performance of -2.57%. Investors looking further ahead will note that the Price to next year’s EPS is 20.72%.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *